JP2012530761A5 - - Google Patents

Download PDF

Info

Publication number
JP2012530761A5
JP2012530761A5 JP2012516745A JP2012516745A JP2012530761A5 JP 2012530761 A5 JP2012530761 A5 JP 2012530761A5 JP 2012516745 A JP2012516745 A JP 2012516745A JP 2012516745 A JP2012516745 A JP 2012516745A JP 2012530761 A5 JP2012530761 A5 JP 2012530761A5
Authority
JP
Japan
Prior art keywords
protein
immunogenic composition
composition according
domain
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2012516745A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012530761A (ja
JP5796011B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2010/059006 external-priority patent/WO2010149743A2/en
Publication of JP2012530761A publication Critical patent/JP2012530761A/ja
Publication of JP2012530761A5 publication Critical patent/JP2012530761A5/ja
Application granted granted Critical
Publication of JP5796011B2 publication Critical patent/JP5796011B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2012516745A 2009-06-24 2010-06-24 ワクチン Active JP5796011B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US21995809P 2009-06-24 2009-06-24
US61/219,958 2009-06-24
PCT/EP2010/059006 WO2010149743A2 (en) 2009-06-24 2010-06-24 Vaccine

Publications (3)

Publication Number Publication Date
JP2012530761A JP2012530761A (ja) 2012-12-06
JP2012530761A5 true JP2012530761A5 (enExample) 2013-08-15
JP5796011B2 JP5796011B2 (ja) 2015-10-21

Family

ID=42797417

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2012516745A Active JP5796011B2 (ja) 2009-06-24 2010-06-24 ワクチン

Country Status (13)

Country Link
US (1) US8889146B2 (enExample)
EP (1) EP2445527A2 (enExample)
JP (1) JP5796011B2 (enExample)
KR (1) KR20120093811A (enExample)
CN (1) CN102548578A (enExample)
AU (1) AU2010264686A1 (enExample)
CA (1) CA2766205A1 (enExample)
EA (1) EA201270062A1 (enExample)
IL (1) IL217008A0 (enExample)
MX (1) MX2012000036A (enExample)
SG (1) SG176807A1 (enExample)
WO (1) WO2010149743A2 (enExample)
ZA (1) ZA201109164B (enExample)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5711972B2 (ja) * 2007-12-24 2015-05-07 アイディー バイオメディカル コーポレイション オブ ケベック 組換えrsv抗原
PT2445526T (pt) 2009-06-24 2016-08-16 Glaxosmithkline Biologicals Sa Antigénios de rsv recombinantes
PL3178490T3 (pl) 2009-07-15 2022-08-01 Glaxosmithkline Biologicals S.A. Kompozycje białka f rsv i sposoby ich wytwarzania
PL2667892T3 (pl) 2011-01-26 2019-09-30 Glaxosmithkline Biologicals Sa Schemat szczepień przeciwko rsv
CA2825722A1 (en) * 2011-01-28 2012-08-02 Medimmune, Llc Expression of soluble viral fusion glycoproteins in mammalian cells
ES2651143T3 (es) 2011-05-13 2018-01-24 Glaxosmithkline Biologicals Sa Antígenos de F de prefusión del VRS
WO2013031827A1 (ja) 2011-08-29 2013-03-07 国立大学法人徳島大学 Rsv粘膜ワクチン
TR201808733T4 (tr) * 2011-10-03 2018-07-23 Mx Adjuvac Ab Kanser tedavisini ve gıda ile ilgili bileşikleri içeren tıp alanlarında amfipatik veya hidrofobik moleküller için taşıyıcı olarak nano-parçacıklar, preparasyon için proses ve bunların kullanımı.
EP2828293B1 (en) * 2012-03-20 2017-10-25 Humabs Biomed S.A. Antibodies that neutralize rsv, mpv and pvm and uses thereof
EA039682B1 (ru) * 2012-06-04 2022-02-28 Хумабс Биомед Са Антитела, нейтрализующие rsv, mpv и pvm, и их применения
CN102743750B (zh) * 2012-07-09 2013-11-20 江苏省农业科学院 一种复方免疫增强剂、禽用疫苗及其制备方法
BR112015002131B1 (pt) 2012-08-01 2022-11-01 Bavarian Nordic A/S Vírus vaccinia ankara modificado (mva) recombinante, composição farmacêutica e uso do referido mva recombinante
US20140037680A1 (en) 2012-08-06 2014-02-06 Glaxosmithkline Biologicals, S.A. Novel method
WO2014024026A1 (en) 2012-08-06 2014-02-13 Glaxosmithkline Biologicals S.A. Method for eliciting in infants an immune response against rsv and b. pertussis
EP2922570A1 (en) * 2012-11-20 2015-09-30 GlaxoSmithKline Biologicals SA Rsv f prefusion trimers
US9738689B2 (en) 2013-03-13 2017-08-22 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Prefusion RSV F proteins and their use
CN105473604B (zh) * 2013-03-13 2021-01-22 美国政府(由卫生和人类服务部的部长所代表) 融合前rsv f蛋白和其用途
US9060975B2 (en) * 2013-03-14 2015-06-23 Mucosis Bv Heat-stable respiratory syncytial virus F protein oligomers and their use in immunological compositions
BR112015025392A2 (pt) * 2013-04-08 2017-10-10 Medimmune Llc composição de vacina e método de utilização
CN110590916A (zh) 2013-04-25 2019-12-20 扬森疫苗与预防公司 稳定化的可溶性融合前rsv f多肽
KR102313153B1 (ko) 2013-06-17 2021-10-15 얀센 백신스 앤드 프리벤션 비.브이. 안정화된 가용성 예비융합 rsv f 폴리펩타이드
KR20160040290A (ko) 2013-08-05 2016-04-12 글락소스미스클라인 바이오로지칼즈 에스.에이. 조합 면역원성 조성물
EP3035959A1 (en) 2013-08-21 2016-06-29 CureVac AG Combination vaccine
US9322037B2 (en) * 2013-09-06 2016-04-26 President And Fellows Of Harvard College Cas9-FokI fusion proteins and uses thereof
EP3236998A1 (en) 2014-12-24 2017-11-01 The U.S.A. as represented by the Secretary, Department of Health and Human Services Recombinant metapneumovirus f proteins and their use
WO2016144675A1 (en) * 2015-03-06 2016-09-15 Medimmune, Llc Vaccine dose and use thereof
JP7189014B2 (ja) 2015-07-07 2022-12-13 ヤンセン ファッシンズ アンド プリベンション ベーフェー Rsvに対するワクチン
US10457708B2 (en) 2015-07-07 2019-10-29 Janssen Vaccines & Prevention B.V. Stabilized soluble pre-fusion RSV F polypeptides
MA47016A (fr) 2015-10-22 2018-08-29 Modernatx Inc Vaccins contre les virus respiratoires
MY205060A (en) 2015-12-23 2024-09-30 Pfizer Rsv f protein mutants
KR20220041966A (ko) 2016-04-05 2022-04-01 얀센 백신스 앤드 프리벤션 비.브이. 안정화된 용해성 융합-전 rsv f 단백질
BR112018070323A2 (pt) 2016-04-05 2019-01-29 Janssen Vaccines & Prevention Bv vacina contra rsv
CN105693829B (zh) * 2016-04-14 2022-03-15 青岛易邦生物工程有限公司 一种b型禽偏肺病毒f蛋白
MA45052A (fr) 2016-05-18 2019-03-27 Modernatx Inc Polynucléotides codant pour jagged1 pour le traitement du syndrome d'alagille
IL264119B2 (en) 2016-05-30 2023-04-01 Janssen Vaccines Prevention B V f proteins of rsv are stabilized before fusion
WO2017207477A1 (en) 2016-05-30 2017-12-07 Janssen Vaccines & Prevention B.V. Stabilized pre-fusion rsv f proteins
CN106119287B (zh) * 2016-08-29 2019-10-11 广东华南疫苗股份有限公司 一种表达呼吸道合胞病毒f蛋白的重组载体及方法
US11078239B2 (en) * 2016-10-25 2021-08-03 The United States Of America, As Represented By The Secretary, Dept. Of Health And Human Services Prefusion PIV F immunogens and their use
TWI683826B (zh) * 2016-11-22 2020-02-01 國立臺灣大學 重組rsv抗原
MA50335A (fr) 2016-12-08 2020-08-19 Modernatx Inc Vaccins à acide nucléique contre des virus respiratoires
EP3595676A4 (en) 2017-03-17 2021-05-05 Modernatx, Inc. RNA VACCINES AGAINST ZOONOSES
CA3061678A1 (en) 2017-05-15 2018-11-22 Janssen Vaccines & Prevention B.V. Stable virus-containing composition
KR102658198B1 (ko) 2017-05-15 2024-04-16 얀센 백신스 앤드 프리벤션 비.브이. 안정한 바이러스 함유 조성물
AU2018267971A1 (en) 2017-05-17 2019-11-07 Janssen Vaccines & Prevention B.V. Methods and compositions for inducing protective immunity against RSV infection
SG11202001458SA (en) 2017-09-15 2020-03-30 Janssen Vaccines & Prevention Bv Method for the safe induction of immunity against rsv
WO2019063844A1 (en) * 2017-09-29 2019-04-04 Universiteit Antwerpen VACCINATION AGAINST SYNCYTIAL RESPIRATORY VIRUS
WO2019092002A1 (en) * 2017-11-07 2019-05-16 Valneva Se Pharmaceutical compositions for treatment or prevention of viral infections
WO2019148101A1 (en) 2018-01-29 2019-08-01 Modernatx, Inc. Rsv rna vaccines
JOP20210106A1 (ar) 2018-11-13 2023-01-30 Janssen Vaccines And Prevention B V بروتينات rsv f سابقة الاندماج مستقرة
WO2020167813A1 (en) * 2019-02-11 2020-08-20 Emory University Chimeric rsv and hmpv f proteins, immunogenic compositions, and methods of use
US11351242B1 (en) 2019-02-12 2022-06-07 Modernatx, Inc. HMPV/hPIV3 mRNA vaccine composition
CN114127101A (zh) 2019-05-20 2022-03-01 瓦尔尼瓦公司 用于治疗或预防呼吸道感染的亚单位疫苗
JP2023513073A (ja) * 2020-01-30 2023-03-30 モデルナティエックス インコーポレイテッド 呼吸器系ウイルス免疫化組成物
TW202233232A (zh) 2020-11-06 2022-09-01 法商賽諾菲公司 遞送mRNA疫苗的脂質奈米顆粒
MX2023009447A (es) * 2021-02-12 2023-10-06 Merck Sharp & Dohme Llc Anticuerpos que se unen a metapneumovirus, proteínas antigénicas de metapneumovirus, y usos de los mismos.
AU2022221983A1 (en) 2021-02-19 2023-08-17 Janssen Vaccines & Prevention B.V. Stabilized pre-fusion rsv fb antigens
KR20240118795A (ko) * 2021-11-30 2024-08-05 사노피 파스퇴르 인크 인간 메타뉴모바이러스 바이러스 벡터-기반 백신
KR20240118798A (ko) * 2021-11-30 2024-08-05 사노피 파스퇴르 인크 인간 메타뉴모바이러스 백신

Family Cites Families (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235877A (en) 1979-06-27 1980-11-25 Merck & Co., Inc. Liposome particle containing viral or bacterial antigenic subunit
US4372945A (en) 1979-11-13 1983-02-08 Likhite Vilas V Antigen compounds
IL61904A (en) 1981-01-13 1985-07-31 Yeda Res & Dev Synthetic vaccine against influenza virus infections comprising a synthetic peptide and process for producing same
US4436727A (en) 1982-05-26 1984-03-13 Ribi Immunochem Research, Inc. Refined detoxified endotoxin product
US4866034A (en) 1982-05-26 1989-09-12 Ribi Immunochem Research Inc. Refined detoxified endotoxin
SE8205892D0 (sv) 1982-10-18 1982-10-18 Bror Morein Immunogent membranproteinkomplex, sett for framstellning och anvendning derav som immunstimulerande medel och sasom vaccin
US4707543A (en) 1985-09-17 1987-11-17 The United States Of America As Represented By The Secretary Of The Army Process for the preparation of detoxified polysaccharide-outer membrane protein complexes, and their use as antibacterial vaccines
US5149650A (en) 1986-01-14 1992-09-22 University Of North Carolina At Chapel Hill Vaccines for human respiratory virus
US4877611A (en) 1986-04-15 1989-10-31 Ribi Immunochem Research Inc. Vaccine containing tumor antigens and adjuvants
CA1331443C (en) 1987-05-29 1994-08-16 Charlotte A. Kensil Saponin adjuvant
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
US5726292A (en) 1987-06-23 1998-03-10 Lowell; George H. Immuno-potentiating systems for preparation of immunogenic materials
US5278302A (en) 1988-05-26 1994-01-11 University Patents, Inc. Polynucleotide phosphorodithioates
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
US6245549B1 (en) * 1990-06-28 2001-06-12 Connaught Laboratories Limited Production of virus and purification of viral envelope proteins for vaccine use
GB9120221D0 (en) 1991-09-23 1991-11-06 Smithkline Beecham Biolog Novel compounds
GB9200117D0 (en) 1992-01-06 1992-02-26 Connaught Lab Production of recombinant chimeric proteins for vaccine use
NZ253137A (en) 1992-06-25 1996-08-27 Smithkline Beecham Biolog Vaccine comprising antigen and/or antigenic composition, qs21 (quillaja saponaria molina extract) and 3 de-o-acylated monophosphoryl lipid a.
EP0689454B2 (en) 1993-03-23 2005-02-23 SMITHKLINE BEECHAM BIOLOGICALS s.a. Vaccine compositions containing 3-o deacylated monophosphoryl lipid a
US5961970A (en) 1993-10-29 1999-10-05 Pharmos Corporation Submicron emulsions as vaccine adjuvants
ES2149340T3 (es) 1993-11-17 2000-11-01 Om Pharma Disacaridos de glucosamina, metodo para su preparacion, composicion farmaceutica que los comprende, y su uso.
WO1995026204A1 (en) 1994-03-25 1995-10-05 Isis Pharmaceuticals, Inc. Immune stimulation by phosphorothioate oligonucleotide analogs
FR2718452B1 (fr) 1994-04-06 1996-06-28 Pf Medicament Elément d'immunogène, agent immunogène, composition pharmaceutique et procédé de préparation.
DE69535905D1 (de) 1994-07-15 2009-02-26 Coley Pharm Group Inc Immunomodulatorische Oligonukleotide
AUPM873294A0 (en) 1994-10-12 1994-11-03 Csl Limited Saponin preparations and use thereof in iscoms
UA56132C2 (uk) 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
US5666153A (en) 1995-10-03 1997-09-09 Virtual Shopping, Inc. Retractable teleconferencing apparatus
US5856462A (en) 1996-09-10 1999-01-05 Hybridon Incorporated Oligonucleotides having modified CpG dinucleosides
US6113918A (en) 1997-05-08 2000-09-05 Ribi Immunochem Research, Inc. Aminoalkyl glucosamine phosphate compounds and their use as adjuvants and immunoeffectors
US6303347B1 (en) 1997-05-08 2001-10-16 Corixa Corporation Aminoalkyl glucosaminide phosphate compounds and their use as adjuvants and immunoeffectors
US6764840B2 (en) 1997-05-08 2004-07-20 Corixa Corporation Aminoalkyl glucosaminide phosphate compounds and their use as adjuvants and immunoeffectors
US7208161B1 (en) 1997-05-23 2007-04-24 The United States Of America, Represented By The Secretary, Department Of Health And Human Services Production of attenuated parainfluenza virus vaccines from cloned nucleotide sequences
WO1999014334A1 (en) 1997-09-19 1999-03-25 American Cyanamid Company Peptides derived from the attachment (g) protein of respiratory syncytial virus
GB9727262D0 (en) 1997-12-24 1998-02-25 Smithkline Beecham Biolog Vaccine
AU7924598A (en) 1998-06-08 1999-12-30 Sca Emballage France Fast flattening packaging
HUP0102475A3 (en) 1998-06-30 2001-12-28 Om Pharma Novel acyl pseudodipeptides, preparation method and pharmaceutical compositions containing same
DE122007000087I1 (de) 1998-10-16 2008-03-27 Glaxosmithkline Biolog Sa Adjuvanzsysteme und impfstoffe
US6551600B2 (en) 1999-02-01 2003-04-22 Eisai Co., Ltd. Immunological adjuvant compounds compositions and methods of use thereof
US20040006242A1 (en) 1999-02-01 2004-01-08 Hawkins Lynn D. Immunomodulatory compounds and method of use thereof
AU1581400A (en) 1999-12-22 2001-07-03 Om Pharma Acyl pseudopeptides bearing a functionalised auxiliary spacer
US20040161846A1 (en) 2000-11-22 2004-08-19 Mason Anthony John Method of expression and agents identified thereby
ES2330201T3 (es) 2001-01-26 2009-12-07 Selexis S.A. Regiones de union a la matriz y metodos para el uso de las mismas.
MXPA03008154A (es) 2001-03-09 2004-11-12 Id Biomedical Corp Quebec Novedoso adyuvante de vacuna de proteosoma-liposacarido.
ATE404561T1 (de) 2001-04-17 2008-08-15 Dainippon Sumitomo Pharma Co Neue adeninderivate
US20040014779A1 (en) 2001-11-16 2004-01-22 3M Innovative Properties Company Methods and compositions related to IRM compounds and toll-like recptor pathways
DE10221836A1 (de) * 2002-05-16 2003-12-04 Lohmann Animal Health Gmbh Attenuierung von Metapneumovirus
AU2003256823B9 (en) * 2002-07-25 2009-01-08 Medimmune, Llc Methods of treating and preventing RSV, hMPV, and PIV using anti-RSV, anti-hMPV, and anti-PIV antibodies
JP2006517974A (ja) 2003-02-13 2006-08-03 スリーエム イノベイティブ プロパティズ カンパニー Irm化合物およびトル様受容体8に関する方法および組成物
US7563449B2 (en) 2003-04-21 2009-07-21 Pfizer Inc, Methods for reducing cattle reproductive diseases
CN1813061B (zh) * 2003-04-25 2013-05-29 免疫医疗有限责任公司 重组副流感病毒表达系统以及包含源自间质肺病毒的异种抗原的疫苗
US7368537B2 (en) 2003-07-15 2008-05-06 Id Biomedical Corporation Of Quebec Subunit vaccine against respiratory syncytial virus infection
EP1959011B1 (en) 2003-10-24 2012-03-28 Selexis S.A. High efficiency gene transfer and expression in mammalian cells by a multiple transfection procedure of matrix attachment region sequences
FR2873378A1 (fr) 2004-07-23 2006-01-27 Pierre Fabre Medicament Sa Complexes immunogenes, leur procede de preparation et leur utilisation dans des compositions pharmaceutiques
GB0422439D0 (en) 2004-10-08 2004-11-10 European Molecular Biology Lab Embl Inhibitors of infection
TWI457133B (zh) 2005-12-13 2014-10-21 Glaxosmithkline Biolog Sa 新穎組合物
WO2008114149A2 (en) * 2007-03-21 2008-09-25 Id Biomedical Corporation Of Quebec Chimeric antigens
WO2008154456A2 (en) * 2007-06-06 2008-12-18 Nationwide Children's Hospital, Inc. Methods and compositions relating to viral fusion proteins
ES2658347T3 (es) 2007-08-13 2018-03-09 Glaxosmithkline Biologicals Sa Vacunas
JP5711972B2 (ja) 2007-12-24 2015-05-07 アイディー バイオメディカル コーポレイション オブ ケベック 組換えrsv抗原
PT2445526T (pt) * 2009-06-24 2016-08-16 Glaxosmithkline Biologicals Sa Antigénios de rsv recombinantes

Similar Documents

Publication Publication Date Title
JP2012530761A5 (enExample)
JP2012530504A5 (enExample)
US20250171501A1 (en) A subunit vaccine for treatment or prevention of a respiratory tract infection
RU2723039C2 (ru) Мутанты белка f rsv
HRP20161353T1 (hr) Rekombinantni rsv antigeni
JP2010522540A5 (enExample)
JP7189014B2 (ja) Rsvに対するワクチン
FI2970398T3 (fi) Rsv f -prefuusioproteiineja ja niiden käyttö
US9060975B2 (en) Heat-stable respiratory syncytial virus F protein oligomers and their use in immunological compositions
JP2011528222A5 (enExample)
JP2008529558A5 (enExample)
JP2011502479A5 (enExample)
JP2016509011A5 (enExample)
JP2010500399A5 (enExample)
JP2016539946A5 (enExample)
JP2013517783A5 (enExample)
JP2013507907A5 (enExample)
AU2014212268B2 (en) Respiratory Syncytial Virus F protein epitopes
EA202090738A1 (ru) Способ безопасного индуцирования иммунитета против rsv
JP2015521467A5 (enExample)
JP2011250797A5 (enExample)
RU2014117068A (ru) Вакцина на основе рекомбинантных наночастиц f из rsv против респираторно-синцитиального вируса
JP2015500827A5 (enExample)
JP2015509707A5 (enExample)
JP2014507146A5 (enExample)